Leadership Overview
Daiichi Sankyo US has 7 executives leading key functions including strategy, oncology development, research operations, risk management, therapeutic oversight, human resources, and corporate leadership.
Focused on advancing oncology through scientific innovation, Daiichi Sankyo US delivers practice-changing antibody drug conjugates to improve patient outcomes and establish new standards of care.
Focused on advancing oncology through scientific innovation, Daiichi Sankyo US delivers practice-changing antibody drug conjugates to improve patient outcomes and establish new standards of care.
Leadership Roles at Daiichi Sankyo US
Dakota Micanopy - Chief Executive Officer
Dakota Micanopy, the Chief Executive Officer at Daiichi Sankyo US, directs the overarching strategic vision for the organization. Micanopy architects the long-term growth trajectory by prioritizing the development of antibody drug conjugates and innovative oncology therapies. Overseeing the entire corporate structure, the Chief Executive Officer ensures alignment between research initiatives and commercial objectives to address critical medical needs. This leadership role involves managing high-level stakeholder relationships and driving the company toward global market leadership. By fostering a culture of scientific excellence, Dakota Micanopy accelerates the delivery of practice-changing medicines to patients. The Chief Executive Officer maintains rigorous oversight of operational performance, ensuring that the company remains at the forefront of the pharmaceutical industry. Through strategic resource allocation, Micanopy secures the necessary infrastructure to support sustained innovation and long-term value creation for healthcare professionals and patients across diverse international markets.
Naoki Hatakeyama - President
Naoki Hatakeyama, the President at Daiichi Sankyo US, directs the operational execution of the company's business strategy. Hatakeyama architects the commercialization efforts for the portfolio of antibody drug conjugates and innovative therapies. Overseeing the integration of regional operations with global objectives, the President ensures that the company effectively addresses the medical needs of patients and healthcare professionals. This role involves managing the intersection of research, development, and market access to maximize the impact of new treatments. By driving operational excellence, Naoki Hatakeyama supports the company's commitment to advancing new standards of care. The President maintains a focus on achieving sustainable growth while upholding the highest scientific and ethical standards. Through strategic leadership, Hatakeyama ensures that the organization remains a leader in the healthcare industry, consistently delivering value through innovation and technology to improve patient outcomes across the United States and beyond.
Erin Mulrooney - Senior Director, Chief of Staff, Early Development Oncology
Erin Mulrooney, the Senior Director, Chief of Staff, Early Development Oncology at Daiichi Sankyo US, coordinates the strategic execution of early-stage oncology research programs. Mulrooney manages the operational flow between clinical development teams and executive leadership to ensure rapid advancement of the antibody drug conjugate portfolio. Overseeing the integration of scientific data into actionable development plans, the Senior Director, Chief of Staff, Early Development Oncology drives efficiency across complex research pipelines. This role involves facilitating cross-functional collaboration to meet critical milestones in the drug discovery process. By optimizing internal workflows, Erin Mulrooney directly impacts the speed at which new therapies reach clinical trials. The Senior Director, Chief of Staff, Early Development Oncology maintains a focus on high-impact research outcomes, ensuring that early development efforts align with the broader mission of transforming patient lives through innovative technology and scientific rigor within the global healthcare landscape.
Theresa Creedon - Director, Change Lead, Research and Development Change and Enablement and Interim Chief of Staff Research and Development Operations
Theresa Creedon, the Director, Change Lead, Research and Development Change and Enablement and Interim Chief of Staff Research and Development Operations at Daiichi Sankyo US, manages organizational transformation within the research division. Creedon architects frameworks that enable seamless transitions during the implementation of new R&D technologies and processes. Overseeing operational enablement, the Director, Change Lead, Research and Development Change and Enablement and Interim Chief of Staff Research and Development Operations ensures that research teams possess the tools required for high-performance drug development. This role involves aligning operational strategies with the company's commitment to oncology innovation. By streamlining internal procedures, Theresa Creedon enhances the productivity of scientists and clinical researchers. The Director, Change Lead, Research and Development Change and Enablement and Interim Chief of Staff Research and Development Operations supports the broader R&D mission by fostering an environment of continuous improvement and agility, ultimately facilitating the rapid delivery of life-saving therapies to patients.
Brittany Pilcher - Global Compliance & Risk Management Chief of Staff
Brittany Pilcher, the Global Compliance & Risk Management Chief of Staff at Daiichi Sankyo US, directs the strategic oversight of regulatory adherence and enterprise risk mitigation. Pilcher architects robust compliance programs that protect the integrity of the company's oncology research and commercial operations. Overseeing the identification and management of potential risks, the Global Compliance & Risk Management Chief of Staff ensures that all business activities align with international healthcare standards. This role involves coordinating with legal and operational departments to maintain a culture of transparency and ethical conduct. By implementing proactive risk management strategies, Brittany Pilcher safeguards the company's reputation and operational continuity. The Global Compliance & Risk Management Chief of Staff supports the organization's mission by ensuring that innovation in drug development proceeds within a secure and compliant framework, thereby protecting the interests of patients, healthcare professionals, and stakeholders across the global pharmaceutical market.
Alice Yama-Dang - Chief of Staff, Therapeutic Area Oncology
Alice Yama-Dang, the Chief of Staff, Therapeutic Area Oncology at Daiichi Sankyo US, coordinates the strategic initiatives within the oncology business unit. Yama-Dang manages the operational alignment of therapeutic programs to ensure the successful development and commercialization of antibody drug conjugates. Overseeing the integration of clinical insights and market requirements, the Chief of Staff, Therapeutic Area Oncology drives the execution of the company's oncology-focused mission. This role involves facilitating communication between research, clinical, and commercial teams to optimize the delivery of new standards of care. By streamlining project management and resource allocation, Alice Yama-Dang enhances the efficiency of the oncology pipeline. The Chief of Staff, Therapeutic Area Oncology maintains a focus on achieving measurable improvements in patient quality of life. Through rigorous operational oversight, Yama-Dang ensures that the therapeutic area remains responsive to the evolving needs of healthcare professionals and patients in the competitive oncology landscape.
Simon King - Chief People Officer
Simon King, the Chief People Officer at Daiichi Sankyo US, directs the human capital strategy to support the company's scientific and commercial goals. King architects talent acquisition, development, and retention programs that foster a culture of innovation and excellence. Overseeing organizational design and employee engagement, the Chief People Officer ensures that the workforce remains aligned with the mission of transforming lives through oncology research. This role involves partnering with executive leadership to build high-performing teams capable of navigating the complexities of the pharmaceutical industry. By cultivating a diverse and inclusive environment, Simon King drives the organizational agility necessary for sustained growth. The Chief People Officer maintains a focus on professional development, ensuring that employees possess the expertise required to advance new standards of care. Through strategic workforce planning, King supports the company's ability to attract top-tier talent dedicated to delivering life-changing medicines to patients worldwide.
Explore Leadership Teams in Manufacturing
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide. Novartis maintains a significant presence in scientific research, with extensive operations spanning across Europe, North America, Asia, and other global regions.
Company Leadership MH
FM
MR
BeOne Medicines is a global biotechnology and pharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative cancer treatments. Its research and development programs target hematologic malignancies and solid tumors, with a mission to expand access to effective cancer therapies worldwide.
Company Leadership
AR
NO
LZ
Promega Corporation is a global leader in biochemistry and molecular biology, specializing in the development of innovative, high-value products for the life sciences. Their extensive product range includes solutions for cellular biology, genetic analysis, protein analysis, and clinical diagnostics. Promega serves a diverse clientele, including researchers in academia, biotechnology, and pharmaceutical industries. The company is committed to providing science-driven solutions and personalized service to accelerate drug discovery and enhance research outcomes.
Company Leadership
KM

KY
American Regent, Inc, a Daiichi Sankyo Group Company, develops, manufactures, and supplies high quality sterile injectables for healthcare providers, clinics and hospitals across the United States and Canada. We have locations in New York, Ohio, and Pennsylvania and sales territories nationwide.
Company Leadership
RT

